ClinicalTrials.gov
ClinicalTrials.gov Menu

Trial of the Safety and Immunogenicity of an Oral, Replicating Ad26 Vectored HIV-1 Vaccine

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02366013
Recruitment Status : Completed
First Posted : February 19, 2015
Last Update Posted : November 21, 2016
Sponsor:
Collaborators:
University of Rochester
Beth Israel Deaconess Medical Center
Information provided by (Responsible Party):
International AIDS Vaccine Initiative

Brief Summary:
This is a dose escalation study to test the safety and immunogenicity of an oral HIV-1 vaccine.

Condition or disease Intervention/treatment Phase
HIV Biological: rcAd26.MOS1.HIV-Env 1x10^8 vp Biological: rcAd26.MOS1.HIV-Env 1x10^9 vp Biological: rcAd26.MOS1.HIV-Env 1x10^10 vp Biological: rcAd26.MOS1.HIV-Env 1x10^11 vp Phase 1

Detailed Description:

This study is a phase I dose-escalation randomized, double blind, placebo-controlled study designed to evaluate the safety and immunogenicity of rcAd26.MOS1.HIV-Env, an oral replicating adenovirus 26 vector vaccine in healthy HIV-1 uninfected adults. The vaccine will be administered orally at a single time point (Day 0) at one of four dose levels depending on study group: 1 x 10^8 virus particles (vp), 1 x 10^9 vp, 1 x 10^10 vp and 1 x 10^11 vp. Volunteers will be randomized to vaccine: placebo in a 5:1 ratio in each group.

Volunteers will be screened up to 56 days before vaccination and will be followed for 12 months after vaccination.

Because the vaccine is replication competent, volunteers will be housed in an isolation unit from day -2 through day 9. Household contacts will also be enrolled and tested for possible transmission.


Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 22 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Prevention
Official Title: A Phase 1 Clinical Trial of the Safety and Immunogenicity of an Oral, Replicating Adenovirus 26 Vector Vaccine for HIV-1 (rcAd26.MOS1.HIV-Env) in Healthy HIV-1-uninfected Adults
Study Start Date : January 2015
Actual Primary Completion Date : June 2016
Actual Study Completion Date : June 2016

Resource links provided by the National Library of Medicine

MedlinePlus related topics: HIV/AIDS

Arm Intervention/treatment
Experimental: Group 1
1 dose of rcAd26.MOS1.HIV-Env 1x10^8 vp or placebo
Biological: rcAd26.MOS1.HIV-Env 1x10^8 vp
1 oral capsule, 1x10^8 vp/capsule or 1 placebo capsule; 5:1 vaccine:placebo

Experimental: Group 2
1 dose of rcAd26.MOS1.HIV-Env 1x10^9 vp or placebo
Biological: rcAd26.MOS1.HIV-Env 1x10^9 vp
10 oral capsules, 1x10^8 vp/capsule or 10 placebo capsules; 5:1 vaccine:placebo

Experimental: Group 3
1 dose of rcAd26.MOS1.HIV-Env 1x10^10 vp or placebo
Biological: rcAd26.MOS1.HIV-Env 1x10^10 vp
1 oral capsule, 1x10^10 vp/capsule or 1 placebo capsule; 5:1 vaccine:placebo

Experimental: Group 4
1 dose of rcAd26.MOS1.HIV-Env 1x10^11 vp or placebo
Biological: rcAd26.MOS1.HIV-Env 1x10^11 vp
10 oral capsules, 1x10^10 vp/capsule or 10 placebo capsules; 5:1 vaccine:placebo




Primary Outcome Measures :
  1. Safety and tolerability as measured by number of volunteers reporting the following: [ Time Frame: 4 Months post-vaccination ]
    • Any adverse events within 4 months following vaccination (SAEs within 12 months following vaccination)
    • Moderate or greater unsolicited adverse events related to study product (i.e., suspected adverse reactions) within 4 weeks post-vaccination
    • Moderate or greater solicited reactions within 9 days post-vaccination


Secondary Outcome Measures :
  1. Proportion (95%CI) of volunteers per dose group with positive shedding responses and mean response per group with 95% CI. [ Time Frame: 28 days ]
    o Rectal/oral shedding: real-time PCR for rcAd26.MOS1.HIV-Env at 1, 2, 3, 4, 5, 6, 7, 8, 9, 12, 17, 21, 7, 12, 21, and 28 days after vaccination.

  2. Proportion of volunteers per dose group with positive immunological responses and mean response (e.g. GMT) per group with 95% CI. [ Time Frame: 12 Months ]
    • Cellular immunogenicity: Env-specific ELISPOT responses at 4 weeks after vaccination.
    • Humoral immunogenicity: Env-specific binding antibody titers at 4 weeks after vaccination.
    • Durability of responses: immunogenicity assays at 4, 8 and 12 months after vaccination.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 40 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Age 18-40 years old.
  • Ability and willingness to provide informed consent.
  • Complete an assessment of understanding
  • Available for the duration of the trial, including willingness to be kept in an isolation facility
  • From Day 10 through 4 months following vaccination must reside alone or with no more than 2 adults (age 18-60) and no minors under age 18
  • Good general health as shown by medical history, physical exam, and screening
  • Willing to undergo HIV testing and willing to receive risk reduction counseling
  • All female volunteers must be willing to undergo urine pregnancy tests
  • Sexually active males must be willing to use an effective method of contraception until at least 4 months after vaccination
  • Women of child bearing potential commit to use an effective method of contraception when sexually active with males for 4 months after vaccination
  • Willing to forgo donations of blood or any other tissues during the study and, for those who test HIV positive due to trial vaccination (vaccine-induced HIV seroreactivity), until the anti-HIV antibody titers become undetectable
  • Low risk for HIV infection and willing to maintain low-risk behavior for the trial duration

Exclusion Criteria:

  • Confirmed HIV-1 or HIV-2 infection; confirmed HCV, HBV, or syphilis infection
  • Current or planned participation in another clinical trial of an experimental agent during the study period
  • Pregnant or lactating
  • Significant acute or chronic disease, including inflammatory bowel disease or other chronic gastrointestinal disease, immunodeficiency syndrome, or condition requiring immunosuppressant medications
  • Use of anticancer, antituberculosis or other medications considered significant by the investigator within the previous 6 months
  • Receipt of live-attenuated vaccine within the previous 60 days or planned receipt within 60 days after vaccination with Investigational Product (within 14 days for live attenuated influenza vaccine [LAIV]); or receipt of other vaccine (e.g., influenza, pneumococcal), allergy treatment with antigen injections or tuberculin skin test within the previous 14 days or planned receipt within 14 days after vaccination with Investigational Product
  • Receipt of blood transfusion or blood-derived products within the previous 3 months
  • Receipt of HIV vaccine(s) in a prior HIV vaccine trial.
  • Previous severe local or systemic reactions to vaccination
  • History of splenectomy
  • History of seizure in the last 3 years
  • Known autoimmune disease
  • Asthma other than mild, well-controlled asthma.
  • Diabetes mellitus type 1 or type 2
  • Thyroidectomy, or thyroid disease requiring medication during the last 12 months
  • Angioedema within the last 3 years if episodes are considered serious or have required medication within the last 2 years
  • Hypertension
  • Body mass index (BMI) ≥ 40
  • Bleeding disorder diagnosed by a doctor
  • Malignancy (Not excluded: a volunteer with a surgical excision and subsequent observation period that in the investigator's estimation has a reasonable assurance of sustained cure or is unlikely to recur during the study period)
  • Psychiatric condition that compromises safety of the volunteer or precludes compliance with the protocol
  • All healthcare workers with direct patient contact
  • Childcare worker who has direct contact with children
  • Individuals employed as food handlers or otherwise engaged in the preparation or delivery of food outside of their place of residence
  • Positive urine toxicology test

Household contacts 18-60 years of age are also evaluated for eligibility with a more abbreviated list of inclusion/exclusion criteria.


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02366013


Locations
United States, New York
University of Rochester
Rochester, New York, United States, 14642
Sponsors and Collaborators
International AIDS Vaccine Initiative
University of Rochester
Beth Israel Deaconess Medical Center
Investigators
Principal Investigator: John Treanor, MD University of Rochester
Study Chair: Kathryn Stephenson, MD, MPH Beth Israel Deaconess Medical Center

Responsible Party: International AIDS Vaccine Initiative
ClinicalTrials.gov Identifier: NCT02366013     History of Changes
Other Study ID Numbers: rcAd001/IAVI R001
First Posted: February 19, 2015    Key Record Dates
Last Update Posted: November 21, 2016
Last Verified: November 2016

Keywords provided by International AIDS Vaccine Initiative:
HIV
HIV Prevention
HIV Vaccine
Healthy

Additional relevant MeSH terms:
Vaccines
Immunologic Factors
Physiological Effects of Drugs